Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study

2018 ◽  
Vol 19 (11) ◽  
pp. 1449-1458 ◽  
Author(s):  
Tadeusz Robak ◽  
Jie Jin ◽  
Halyna Pylypenko ◽  
Gregor Verhoef ◽  
Noppadol Siritanaratkul ◽  
...  
Keyword(s):  
Overall Survival ◽  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Newly Diagnosed ◽  
Open Label ◽  
Phase 3 ◽  
Mantle Cell ◽  
Open Label Phase

scholarly journals Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study

The Lancet ◽  
2016 ◽  
Vol 387 (10020) ◽  
pp. 770-778 ◽  
Author(s):  
Martin Dreyling ◽  
Wojciech Jurczak ◽  
Mats Jerkeman ◽  
Rodrigo Santucci Silva ◽  
Chiara Rusconi ◽  
...  
Keyword(s):  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Open Label ◽  
Phase 3 ◽  
Mantle Cell ◽  
Open Label Phase

scholarly journals An open‐label phase 2 trial of entospletinib in indolent non‐Hodgkin lymphoma and mantle cell lymphoma

2018 ◽  
Vol 184 (2) ◽  
pp. 215-222 ◽  
Author(s):  
David J. Andorsky ◽  
Kathryn S. Kolibaba ◽  
Sarit Assouline ◽  
Andres Forero‐Torres ◽  
Vicky Jones ◽  
...  
Keyword(s):  
Mantle Cell Lymphoma ◽  
Hodgkin Lymphoma ◽  
Cell Lymphoma ◽  
Phase 2 ◽  
Open Label ◽  
Non Hodgkin Lymphoma ◽  
Phase 2 Trial ◽  
Mantle Cell ◽  
Open Label Phase

Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial

2016 ◽  
Vol 17 (1) ◽  
pp. 48-56 ◽  
Author(s):  
Michael L Wang ◽  
Hun Lee ◽  
Hubert Chuang ◽  
Nicolaus Wagner-Bartak ◽  
Frederick Hagemeister ◽  
...  
Keyword(s):  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Phase 2 ◽  
Single Centre ◽  
Open Label ◽  
Phase 2 Trial ◽  
Mantle Cell ◽  
Open Label Phase

Deferred therapy is associated with improved overall survival in patients with newly diagnosed mantle cell lymphoma

Cancer ◽  
2016 ◽  
Vol 122 (15) ◽  
pp. 2356-2363 ◽  
Author(s):  
Jonathon B. Cohen ◽  
Xuesong Han ◽  
Ahmedin Jemal ◽  
Elizabeth M. Ward ◽  
Christopher R. Flowers
Keyword(s):  
Overall Survival ◽  
Mantle Cell Lymphoma ◽  
Cell Lymphoma ◽  
Newly Diagnosed ◽  
Mantle Cell
Sign in / Sign up

Export Citation Format

Share Document